scholarly journals Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4

1997 ◽  
Vol 322 (2) ◽  
pp. 393-401 ◽  
Author(s):  
Anne M. MURPHY ◽  
W. Reid THOMPSON ◽  
Ling Fan PENG ◽  
Lawrence JONES

Troponin I is a thin-filament contractile protein expressed in striated muscle. There are three known troponin I genes which are expressed in a muscle-fibre-type-specific manner in mature animals. Although the slow skeletal troponin I isoform is expressed in fetal and neonatal heart, the cardiac isoform is restricted in its expression to the myocardium at all developmental stages. To study the regulation of this cardiac-specific and developmentally regulated gene in vitro, the rat cardiac troponin I gene was cloned. Transient transfection assays were performed with troponin I–luciferase fusion plasmids to characterize the regulatory regions of the gene. Proximal regions of the upstream sequence were sufficient to support high levels of expression of the reporter gene in cardiocytes and relatively low levels in other cell types. The highest luciferase activity in the cardiocytes was noted with a plasmid that included the region spanning -896 to +45 of the troponin I genomic sequence. Co-transfection of GATA-4, a recently identified cardiac transcription factor, with troponin I–luciferase constructs permitted high levels of luciferase expression in non-cardiac cells. Electrophoretic mobility-shift assays demonstrated specific binding of GATA-4 to oligonucleotides representative of multiple sites of the troponin I sequence. Mutation of a proximal GATA-4 DNA-binding site decreased transcriptional activation in transfected cardiocytes. These results indicate that the proximal cardiac troponin I sequence is sufficient to support high levels of cardiac-specific gene expression and that the GATA-4 transcription factor regulates troponin I–luciferase expression in vitro.

2001 ◽  
Vol 33 (12) ◽  
pp. 2095-2107 ◽  
Author(s):  
Fumi Takahashi-Yanaga ◽  
Sachio Morimoto ◽  
Keita Harada ◽  
Reiko Minakami ◽  
Fumie Shiraishi ◽  
...  

2010 ◽  
Vol 51 (3) ◽  
pp. 214-217 ◽  
Author(s):  
Akira Funada ◽  
Eiichi Masuta ◽  
Noboru Fujino ◽  
Kenshi Hayashi ◽  
Hidekazu Ino ◽  
...  

2016 ◽  
Vol 130 (24) ◽  
pp. 2277-2278
Author(s):  
Charles S. Redwood

Cardiac troponin I (cTnI) is a key component of the Ca2+-regulatory mechanism of cardiac contractility. It is released into the circulation upon ischaemia and has become established as one of the principal diagnostic biomarkers of myocardial damage. The release of cTnI results in the generation of autoantibodies, and these have been suggested to play a pathogenic role. However, in this Edition of Clinical Science, Han, Y. et al. suggests that cTnI can act independently of immunological involvement, with the protein being found to increase infarct size caused by ischaemia/reperfusion (I/R) prior to the development of cTnI antibody. In vitro work shows that cTnI can induce increases in vascular cell adhesion molecule 1 (VCAM-1) expression and cell adhesion, with toll-like receptor 4 (TLR4) and nuclear factor kappa beta (NF-κB) involved in the downstream signalling.


1997 ◽  
Vol 16 (4) ◽  
pp. 379-382 ◽  
Author(s):  
Akinori Kimura ◽  
Haruhito Harada ◽  
Jeong-Euy Park ◽  
Hirofumi Nishi ◽  
Manatsu Satoh ◽  
...  

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Rachel R Smith ◽  
Michelle K Leppo ◽  
Isotta Chimenti ◽  
John Terrovitis ◽  
Andreas S Barth ◽  
...  

Cardiosphere-derived cells (CDCs) were grown from rat hearts and percutaneous endomyocardial adult human biopsy specimens. Rat CDCs plated as single cells formed clones with a doubling time of 42.2 ± 0.7 hours (n = 9). Clones from rat CDCs divided steadily for 27 days before proliferation spontaneously slowed and morphological changes occurred in most cells. After 56 days, rat clonal populations contained a small fraction of c-Kit + cells as determined by flow cytometry, and large subsets of cells expressing cardiac troponin I, α-smooth muscle actin, and von Willebrand factor as determined by immunofluorescence, indicative of their multipotentiality in vitro . To assess therapeutic potential, acute myocardial infarcts (MIs) were created in immunodeficient mice and actively proliferating polyclonal human CDCs were injected into the border zone. Echocardiographic left ventricular function, histological examination, and immunofluorescence served as endpoints. CDC-injected animals showed no significant deterioration in ejection fraction (EF) from 2 days (EF = 45.2 ± 4.8%) to 6 weeks post-MI (EF = 40.2 ± 4.5%, n = 7, p = NS), in contrast to fibroblast-injected control animals (EF = 42.8 ± 4.3% at 2 days vs 27.3 ± 4.0% at 6 weeks, p < 0.01). At the 6 week endpoint, the CDC group had thicker infarct walls as measured histologically compared to the fibroblast group (0.26 ± 0.03mm vs 0.12 ± 0.01mm, n = 5, p < 0.01). CDC engraftment was determined by immunofluorescence using a human-specific antibody. CDCs stably engrafted for up to 6 weeks and could be found distributed primarily throughout the infarct (57 ± 3% of engrafted CDCs, n = 5 animals), as well as the border zone (30 ± 5%) and viable tissue (13 ± 3%). After 6 weeks, CDCs within the infarct had formed small myocytes with little cytoplasmic cardiac troponin I, while CDCs within the viable myocardium had formed large myocytes with well-defined sarcomeric organization. We conclude that CDCs are clonogenic and spontaneously multipotent in vitro and capable of preserving heart function in a mouse infarct model. Functional preservation is presumably due in part to maintenance of infarct wall thickness, likely secondary to stable CDC engraftment within the infarct, as well as the formation of morphologically mature myocytes throughout the non-infarcted tissue.


2010 ◽  
Vol 12 (6) ◽  
pp. 280-283 ◽  
Author(s):  
Chikako Murakami ◽  
Shigeki Nakamura ◽  
Masamune Kobayashi ◽  
Kazuho Maeda ◽  
Wataru Irie ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document